Les anti-inflammatoires et SARS-CoV-2 (COVID-19)

To date, treatment options for severe COVID-19 remain limited and there is currently no effective drug or vaccine for the treatment or prevention of specific SARS-CoV-2 to treat critically ill patients. A new treatment strategy, in addition to antiviral therapy alone, may be required to have a signi...

Descripción completa

Detalles Bibliográficos
Autores principales: Moutaouakkil, Youssef, Tadlaoui, Yasmina, Latt, Esso Eric Valery, Atbib, Yassine, Cherrah, Yahia, Bennana, Ahmed, Bousliman, Yassir, Lamsaouri, Jamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252016/
http://dx.doi.org/10.1016/j.douler.2020.04.012
Descripción
Sumario:To date, treatment options for severe COVID-19 remain limited and there is currently no effective drug or vaccine for the treatment or prevention of specific SARS-CoV-2 to treat critically ill patients. A new treatment strategy, in addition to antiviral therapy alone, may be required to have a significant impact on clinical outcomes. Immunomodulatory therapy to downregulate cytokine shock may provide information on the treatment of COVID-19. Combined use of an immunomodulatory agent with an antiviral agent may give doctors more time to provide supportive therapy to patients with COVID-19. In this review of the literature, the roles of several anti-inflammatory drugs were reviewed to explore their effectiveness in the fight against SARS-CoV-2.

Ejemplares similares